Total Funding
52
41
Total FundingPost-IPO Equity raised
Growth Score 52 in past quarter
-3 pts
Heat Score 41 in past quarter
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
25791
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
- Robert Ho: Chief Financial Officer
About the Company
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external
environment and that act as the key mediator of the inflammation associated with allergic diseases.
Women Led